La maladie goutteuse

Scuiller, A.; Pascart, Tristan; Bernard, Amélie; Oehler, Erwan

doi:10.1016/j.revmed.2020.02.014

Cited by 29 publications

(20 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum UA level is regulated by UA transport proteins in the kidney and intestine, specifically GLUT9 (SLC2A9), URAT1 (SLC22A12), and ABCG2 (Scuiller et al, 2020). GLUT9, encoded by the SLC2A9 gene, is an important proximal tubular transporter protein for UA and plays a key role in hyperuricemia.…”

Section: Discussionmentioning

confidence: 99%

Effect of Eucommia ulmoides leaves on hyperuricemia and kidney injury induced by a high-fat/high-fructose diet in rats

Gong

Zhang

Liu

et al. 2021

Preprint

View full text Add to dashboard Cite

Eucommia ulmoides leaves have unique advantages in the treatment of metabolic diseases. In this study, network pharmacology and molecular-docking methods were used to predict the effects and action mechanisms of the major components of E. ulmoides leaves on hyperuricemia. Combining literature collection, we used SciFinder and the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform to collect E. ulmoides leaf flavonoid and iridoid components. Swiss Target Prediction, SEA, GeneCards, and the OMIM database were used to obtain core targets, and the STRING protein database was performed as core targets for gene ontology enrichment Set and KEGG analyses. Molecular docking was applied to predict the pathways regulating the metabolism of uric acid. The selected targets and targeting efficacy were validated using a rat model of hyperuricemia and renal injury induced by a high-fat and high-fructose diet. A total of 32 chemical components with effective targets, which regulated the PI3K-AKT pathway and endocrine resistance, were collected. Isoquercetin, kaempferol, and quercetin were predicted via network pharmacology to have potential bioactivities and strong docking binding forces. Molecular docking results showed that iridoids and flavonoids are bound to proteins related to inflammation and uric acid metabolism. In addition, it was verified via animal experiments that an E. ulmoides leaf extract ameliorated hyperuricemia, renal injury, and inflammation, which are closely related to the targets IL-6, TNF-α, TLR4, and GLUT9. In conclusion, E. ulmoides leaf flavonoids and iridoids ameliorate hyperuricemia and uric-acid–induced inflammation through a multi-component, multi-target, and multi-pathway mechanism, which provides a theoretical basis for the development of therapeutics from E. ulmoides leaf components.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Eucommia ulmoides leaves on hyperuricemia and kidney injury induced by a high-fat/high-fructose diet in rats

Gong

Zhang

Liu

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Gout is a metabolic disease, caused by elevation of serum urate level (Scuiller et al, 2020). The prevalence of gout in the world ranges from 0.68%-3.90% and is still increasing steadily (Dalbeth et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis

Guan

Zhang²,

Liu³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Gout is a common disease and is usually treated with uric acid-lowering drugs (the most commonly used of which are febuxostat and allopurinol). However, the cardiovascular safety of febuxostat and allopurinol is still controversial. The purpose of our study is to evaluate the cardiovascular safety of the two drugs in patients with gout using one-stage and two-stage meta-analysis.Methods: PubMed, Embase, CBM, CNKI, WanFang, Central, and VIP were searched from inception to 30 January 2022. Randomized controlled trials which evaluated the cardiovascular safety of febuxostat or allopurinol for treating patients with gout were included. Based on the Kaplan–Meier curves of the two studies, individual patient data (IPD) were extracted and reconstructed. We used time-varying risk ratios (RRs) to summarize time-to-event outcomes, and the RRs of MACE incidence, cardiovascular mortality, and all-cause mortality were calculated by a multi-level flexible hazard regression model in 1-stage meta-analyses. p values were calculated using a log-rank test. At the same time, using the reconstructed IPD, we performed 2-stage meta-analyses to inform the quantitative estimates of time-specific relative risks at the six time points (1 , 2, 3, 4, 5, and 6 years) based on a random-effects model.Results: Two RCTs with 12,318 participants were included. In the incidence of major adverse cardiovascular events between the two regimens, there was no significant difference [RR = 0.99 (95% CI, 0.89–1.11), p = 0.87]; at the same time, there was no significant difference in cardiovascular mortality [RR = 1.17 (95% CI, 0.98–1.40),p = 0.08] or all-cause mortality [RR = 1.03 (95% CI, 0.91–1.17),p = 0.62]. In terms of 2-stage meta-analyses, there was no significant difference in any outcomes at any time point (moderate-to low-certainty evidence).Conclusion: In patients without atherosclerotic disease, febuxostat likely has a similar cardiovascular profile to allopurinol. However, in patients with a history of cardiovascular disease, allopurinol treatment is associated with less cardiovascular mortality as compared with febuxostat.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/#loginpage, identifier PROSPERO, CRD42022325656.

show abstract

“…Real-life observational data show that the majority of patients do not reach targeted SU levels and still experience recurrent flares [ 6 , 9 , 10 ]. Under-prescription of ULT, poor treatment compliance, and fears and beliefs often insufficiently addressed in patient education have been identified as the main barriers for optimal care [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Simple Application and Adherence to Gout Guidelines Enables Disease Control: An Observational Study in French Referral Centres

Jauffret

Ottaviani²,

Latourte

et al. 2022

JCM

View full text Add to dashboard Cite

Background: In a context of therapeutic inertia, the French Society of Rheumatology (SFR) published its first recommendations on gout in 2020, which were deliberately simple and concise. The objectives of the study were to determine the profile of patients referred to French gout-expert centres, and to examine the results of their management and the factors leading to those results. Methods: Three hundred patients attending a first visit for gout management in three French referral centres were retrospectively and randomly included in this multicentre observational study. Visits were performed at baseline (M0) and scheduled for month 6 (M6), month 12 (M12), and month 24 (M24). Results: Patients were 81% male and had a mean age 62.2 ± 15.2 years. Management followed French recommendations after the baseline visit in 94.9% of cases. SU levels were below 6.0 mg/dL in 59.4% of patients at M6, 67.9% at M12, and 78.6% at M24, with increasing clinical improvement (i.e., flare decrease) over 2 years of follow-up. At M24, 50% of patients were treated with allopurinol (313 ± 105 mg/d), which exceeded renal restrictions of doses in 61.5% of them, and 48.2% received febuxostat (84 ± 36 mg/d). The need for a sufficient dosage of ULT was the only predictive factor found for successful achievement of SU levels < 6.0 mg/dL at a given visit. Conclusions: Simple application of gout-management guidelines is feasible in clinical practice and is efficient, with a majority of patients achieving SU targets and clinical improvement.

show abstract

La maladie goutteuse

Cited by 29 publications

References 53 publications

Effect of Eucommia ulmoides leaves on hyperuricemia and kidney injury induced by a high-fat/high-fructose diet in rats

Effect of Eucommia ulmoides leaves on hyperuricemia and kidney injury induced by a high-fat/high-fructose diet in rats

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis

Simple Application and Adherence to Gout Guidelines Enables Disease Control: An Observational Study in French Referral Centres

Contact Info

Product

Resources

About